Tevogen (TVGN) Current Assets (2021 - 2026)
Tevogen's (TVGN) quarterly Current Assets came in at $2.1 million in Q1 2026, down 30.44% on a YoY basis from $3.1 million in Q1 2025, and up 39.05% quarter-over-quarter from $1.5 million in Q4 2025.
Analysis
Tevogen (TVGN) Current Assets (2021 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Current Assets for 6 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Current Assets fell 30.44% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 million (down 30.44% YoY), and the FY2025 full-year result was $1.5 million, down 34.78% from the prior year.
- Current Assets advanced to $2.1 million in Q1 2026 per TVGN's latest filing, from $1.5 million in the prior quarter.
- Across five years, Current Assets topped out at $3.5 million in Q3 2024 and bottomed at $97064.0 in Q1 2023.
- Historically, Current Assets has averaged $1.6 million across 5 years, with a median of $1.7 million in 2023.
- The sharpest annual moves came in 2023 and 2024: Current Assets tumbled 86.78% in 2023, then jumped 2372.51% in 2024.
- Over 5 years, Current Assets stood at $274356.0 in 2022, then surged by 528.01% to $1.7 million in 2023, then jumped by 37.02% to $2.4 million in 2024, then plunged by 34.78% to $1.5 million in 2025, then jumped by 39.05% to $2.1 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $2.1 million, $1.5 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 1.06 Bn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 2.37 Bn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 464.26 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 1.23 Bn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 834.27 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 1.18 Bn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 134.38 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 2.22 Bn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 264.73 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 2.14 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 2.12 Mn |
| Jun 30, 2025 | 2.06 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 2.36 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 399,474.00 |
| Jun 30, 2023 | 699,327.00 |
| Mar 31, 2023 | 97,064.00 |
| Dec 31, 2022 | 274,356.00 |
| Sep 30, 2022 | 418,473.00 |
| Jun 30, 2022 | 594,755.00 |
| Mar 31, 2022 | 734,159.00 |
| Dec 31, 2021 | 791,191.00 |